NCT02658409 - A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study | Biotech Hunter

Enrollment

1,630

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2015

Conditions

Influenza

Interventions

BIOLOGICAL

GC3106(quadrivalent cell-culture based influenza vaccine)

GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1

BIOLOGICAL

Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)

Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1

Trial Locations (1)

Korea University Guro Hospital, Seoul